High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome

被引:29
作者
Rostasy, K.
Wilken, B.
Baumann, M.
Mueller-Deile, K.
Bieber, I.
Gaertner, J.
Moeller, P.
Angelini, P.
Hero, B.
机构
[1] Univ Gottingen, Dept Pediat, Fac Med, D-37075 Gottingen, Germany
[2] Univ Gottingen, Div Paediat Neurol, D-3400 Gottingen, Germany
[3] Klinikum Kassel, Dept Paediat Neurol, Kassel, Germany
[4] Childrens Hosp Auf Bult, Dept Paediat & Paediat Neurol, Hannover, Germany
[5] Univ Wurzburg, Wurzburg, Germany
[6] Klinikum Wolfsburg, Ctr Dev Neurol & Social Paediat, Wolfsburg, Germany
[7] Giannina Gaslini Childrens Hosp, Dept Paediat Haematol & Oncol, Genoa, Italy
[8] Univ Cologne, Dept Paediat Oncol, Cologne, Germany
关键词
children; opsoclonus-myoclonus syndrome; dexamethasone; therapy;
D O I
10.1055/s-2006-955931
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Opsoclonus-myoclonus syndrome (OMS) is a rare movement disorder characterized by chaotic eye movements, myoclonus, and ataxia associated with severe irritability. Different treatment modalities including steroids and cyclophosphamide have been tried in the past often with significant side effects and variable success. Here we present 11 children, diagnosed with OMS between 1999 and 2005 and treated with high dose dexamethasone pulses. Main symptoms at presentation were opsoclonus (11/11), ataxia and/or myoclonus (11/11), irritability (10/11) associated with a neuroblastoma in four children. Number of dexamethasone pulses ranged from 6 to 60 pulses. No major side effects were reported. In 6/11 children a complete and sustained remission of OMS symptoms was achieved after 6 to 29 pulses of dexamethasone. Two children from this group have a normal development and no neurological sequelae. Two further children have minor delays in fine- and gross-motor skills. Two children despite a complete recovery of OMS symptoms have persisting developmental problems. 5/11 children still require regular dexamethasone pulses in addition to daily prednisolone (n = 1) or have received cyclophosphamide pulses meanwhile (n=2). All children continue to have developmental and neurological difficulties. In summary treatment with high dose pulsatile dexamethasone appears to be safe and beneficial in a subgroup of patients with OMS.
引用
收藏
页码:291 / 295
页数:5
相关论文
共 18 条
  • [1] Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus
    Antunes, NL
    Khakoo, Y
    Matthay, KK
    Seeger, RC
    Stram, DO
    Gerstner, E
    Abrey, LE
    Dalmau, J
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2000, 22 (04) : 315 - 320
  • [2] Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome
    Blaes, F
    Fühlhuber, V
    Korfei, M
    Tschernatsch, M
    Behnisch, W
    Rostasy, K
    Hero, B
    Kaps, M
    Preissner, KT
    [J]. ANNALS OF NEUROLOGY, 2005, 58 (02) : 313 - 317
  • [3] Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: An analysis of antigenic targets in neural tissues
    Connolly, AM
    Pestronk, A
    Mehta, S
    Pranzatelli, MR
    Noetzel, MJ
    [J]. JOURNAL OF PEDIATRICS, 1997, 130 (06) : 878 - 884
  • [4] Dexamethasone blocking effects on mu- and delta-opioid-induced seizures involves kappa-opioid activity in the rabbit
    Di Giannuario, A
    Pieretti, S
    Sagratella, S
    Loizzo, A
    [J]. NEUROPSYCHOBIOLOGY, 2001, 43 (03) : 213 - 220
  • [5] KARENFURT M, 2002, NEUROPEDIATRICS, V33, pA52
  • [6] Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004
    Matthay, KK
    Blaes, F
    Hero, B
    Plantaz, D
    De Alarcon, P
    Mitchell, WG
    Pike, M
    Pistoia, V
    [J]. CANCER LETTERS, 2005, 228 (1-2) : 275 - 282
  • [7] Mitchell WG, 2002, PEDIATRICS, V109, P86
  • [8] Long-term outcome in children with opsoclonus-myoclonus associated with localized neuroblastoma: a report from the French Society of Pediatric Oncology
    Plantaz, D
    Michon, J
    Valteau-Couanet, D
    Coze, C
    Chastagner, P
    Bergeron, C
    Nelken, B
    Martelli, H
    Peyroulet, MC
    Carpentier, AF
    Armari-Alla, C
    Pagnier, A
    Rubie, H
    [J]. ARCHIVES DE PEDIATRIE, 2000, 7 (06): : 621 - 628
  • [9] Neurological sequelae of the dancing eye syndrome
    Pohl, KRE
    Pritchard, J
    Wilson, J
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1996, 155 (03) : 237 - 244
  • [10] Immunologic and clinical responses to rituximab in a child with Opsoclonus-Myoclonus syndrome
    Pranzatelli, MR
    Tate, ED
    Travelstead, AL
    Longee, D
    [J]. PEDIATRICS, 2005, 115 (01) : E115 - E119